# Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

> **NCT00328120** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00328120
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-04
- **Final completion:** 2010-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2010-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328120, "Faslodex 500mg Multiple Dose Tolerability Study in BC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00328120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*